Recombinant human interferon alpha-1b (Beijing Tri-Prime Genetic Engineering)

重组人干扰素α1b(北京三元基因工程有限公司)

Report date: 2022/04/18 17:53:05

Base Information

Drug NameRecombinant human interferon alpha-1b (Beijing Tri-Prime Genetic Engineering)
Drug Alias Name重组人基因工程α1b干扰素（北京三元基因工程有限公司）Recombinant human interferon alpha 1b(Beijing Tri-Prime Genetic Engineering)运德素YunDeSu
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsNeoplasmsRespiratory Syncytial Virus InfectionsVirus Diseases +[5] 
Global Approved IndicationsNeoplasmsVirus Diseases
Approved Indications in ChinaNeoplasmsVirus Diseases
Original Approved Country/TerritoryMainland China
Original Approved Date1999/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Tri-Prime Gene Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Tri-Prime Gene Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasmsVirus DiseasesPneumonia +[4] 
Inactive IndicationsRespiratory Syncytial Virus Infections

Other Information

ATC CodeL03AB
Related LinksN/A